Fundamental Analysis of BARINTHUS BIOTHERAPEUTICS PL(NASDAQ:BRNS) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to BRNS. BRNS was compared to 565 industry peers in the Biotechnology industry. BRNS has a great financial health rating, but its profitability evaluates not so good. BRNS has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BRNS has reported negative net income.

In the past year BRNS has reported a negative cash flow from operations.

In the past 5 years BRNS reported 4 times negative net income.

In the past 5 years BRNS always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -30.65%, BRNS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.

BRNS has a better Return On Equity (-36.30%) than 75.22% of its industry peers.

		Industry Rank	Sector Rank
ROA	-30.65%
ROE	-36.3%
ROIC	N/A

ROA(3y)-16.78%

ROA(5y)-38.83%

ROE(3y)-19.08%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BRNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.

BRNS has more shares outstanding than it did 1 year ago.

BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -1.11, we must say that BRNS is in the distress zone and has some risk of bankruptcy.

BRNS has a Altman-Z score of -1.11. This is comparable to the rest of the industry: BRNS outperforms 59.18% of its industry peers.

There is no outstanding debt for BRNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.11

ROIC/WACCN/A

WACC8.84%

2.3 Liquidity

A Current Ratio of 8.93 indicates that BRNS has no problem at all paying its short term obligations.

The Current ratio of BRNS (8.93) is better than 77.54% of its industry peers.

BRNS has a Quick Ratio of 8.93. This indicates that BRNS is financially healthy and has no problem in meeting its short term obligations.

BRNS's Quick ratio of 8.93 is fine compared to the rest of the industry. BRNS outperforms 77.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.93
Quick Ratio	8.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.85% over the past year.

The Revenue has grown by 106.21% in the past year. This is a very strong growth!

Measured over the past years, BRNS shows a very negative growth in Revenue. The Revenue has been decreasing by -45.00% on average per year.

EPS 1Y (TTM)26.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%43.24%

Revenue 1Y (TTM)106.21%

Revenue growth 3Y-45%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

BRNS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.55% yearly.

The Revenue is expected to decrease by -18.92% on average over the next years. This is quite bad

EPS Next Y12.17%

EPS Next 2Y4.65%

EPS Next 3Y1.87%

EPS Next 5Y-12.55%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-18.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BRNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BRNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y4.65%

EPS Next 3Y1.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BRNS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BARINTHUS BIOTHERAPEUTICS PL

NASDAQ:BRNS (11/22/2024, 8:26:58 PM)

0.8947

-0.09 (-9.47%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap35.26M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.65%
ROE	-36.3%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.93
Quick Ratio	8.93
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)26.85%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y12.17%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)106.21%

Revenue growth 3Y-45%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BARINTHUS BIOTHERAPEUTICS PL (BRNS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens